Amarin Corporation PLC (AMRN)

Currency in USD
16.150
+0.340(+2.15%)
Real-time Data·
AMRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.24016.380
52 wk Range
12.96020.900
Key Statistics
Prev. Close
15.81
Open
15.66
Day's Range
15.24-16.38
52 wk Range
12.96-20.9
Volume
16.84K
Average Volume (3m)
71.91K
1-Year Change
28.1746%
Book Value / Share
21.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMRN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.500
Downside
-22.60%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Amarin Corporation PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

0 Buy
1 Hold
1 Sell
Ratings:
2 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 12.500
(-22.60% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Hold12.00-25.70%10.00Maintain30/10/2025
Goldman Sachs
Sell12.00-25.70%7.00Maintain25/06/2025

Amarin Corporation PLC Earnings Call Summary for Q1/2026

  • Amarin reported Q1 2026 revenue of $45.1M, up 7.4% YoY, with operating loss narrowing 32.7% to $11.3M amid 31% expense reduction.
  • Company generated positive cash flow of $6.4M for second consecutive quarter, ending Q1 with $308M in cash and investments.
  • U.S. Vascepa-branded prescriptions increased 17% YoY; European partnership with Recordati delivered significant revenue growth.
  • Management forecasts Q2 2026 EPS of $0.54 and full-year EPS of $2.47, expecting sustained positive cash flow throughout 2026.
  • CEO Thero cited restructuring success; key risks include generic competition, pricing pressures, and regulatory hurdles in international expansion.
Last Updated: 29/04/2026, 10:48 pm
Read Full Transcript

Earnings

Latest Release
29/04/2026
EPS / Forecast
-0.60 / -0.87
Revenue / Forecast
45.13M / --
EPS Revisions
Last 90 days

AMRN Income Statement

Compare AMRN to Peers and Sector

Metrics to compare
AMRN
Peers
Sector
Relationship
P/E Ratio
−9.9x−3.0x−0.4x
PEG Ratio
−0.160.210.00
Price/Book
0.7x1.3x2.6x
Price / LTM Sales
1.5x4.7x3.0x
Upside (Analyst Target)
−20.9%168.0%58.4%
Fair Value Upside
Unlock14.1%8.6%Unlock

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
203.03K0.97%3.21M
Other Institutional Investors
4.55M21.67%71.86M
Public Companies & Retail Investors
16.22M77.36%256.45M
Total
20.97M100.00%331.52M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sarissa Capital Management LP7.98%1,673,39526,456
Acadian Asset Management LLC3.04%636,76910,067

People Also Watch

11.0450
ASTC
-2.00%
5.175
ALTO
-0.86%
7.0400
GTE
-2.36%
98.540
CECO
-1.13%

FAQ

What Is the Amarin (AMRN) Stock Price Today?

The Amarin stock price today is 16.150 USD.

What Stock Exchange Does Amarin Trade On?

Amarin is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Amarin?

The stock symbol for Amarin is "AMRN."

What Is the Amarin Market Cap?

As of today, Amarin market cap is 331.520M USD.

What Is Amarin's Earnings Per Share (TTM)?

The Amarin EPS (TTM) is -1.615.

From a Technical Analysis Perspective, Is AMRN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Amarin Stock Split?

Amarin has split 3 times.

How Many Employees Does Amarin Have?

Amarin has 80 employees.

What is the current trading status of Amarin (AMRN)?

As of 23/06/2026, Amarin (AMRN) is trading at a price of 16.150 USD, with a previous close of 15.810 USD. The stock has fluctuated within a day range of 15.240 USD to 16.380 USD, while its 52-week range spans from 12.960 USD to 20.900 USD.

What Is Amarin (AMRN) Price Target According to Analysts?

The average 12-month price target for Amarin is 12.500 USD, with a high estimate of 13 USD and a low estimate of 12 USD. 0 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Sell. The stock has an -22.60% Downside potential.

What Is the AMRN Premarket Price?

AMRN's last pre-market stock price is 15.000 USD. The pre-market share volume is 80.000, and the stock has decreased by -0.810, or -5.120%.

What Is the AMRN After Hours Price?

AMRN's last after hours stock price is 15.820 USD, the stock has decreased by 0.010, or 0.060%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.